Intended for healthcare professionals


Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes

BMJ 2003; 326 doi: (Published 08 March 2003) Cite this as: BMJ 2003;326:528

This article has a correction. Please see:

  1. Apoor S Gami, instructor in medicinea,
  2. Victor M Montori, assistant professorb,
  3. Patricia J Erwin, head reference librarianc,
  4. Mehmood A Khan, associate professorb,
  5. Steven A Smith, associate professor (

    for the Evidence in Diabetes Enquiry System (EVIDENS) Research Group

  1. a Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
  2. b Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic
  3. c Mayo Medical Libraries, Mayo Clinic
  1. Correspondence to: S A Smith
  • Accepted 17 January 2003

Patients with diabetes are at high risk of coronary heart disease. Leading organisations have recommended that all diabetic patients should be treated as aggressively as patients with established coronary heart disease.1 Randomised trials have shown the efficacy of reducing low density lipoprotein concentrations in patients without coronary heart disease. Large trials and meta-analyses of such trials would be expected to provide information on diabetic patients. We therefore systematically examined the available data on lowering low density lipoprotein concentrations in diabetic patients without coronary heart disease.

Methods and results

The review protocol is available from the authors. We searched Medline and eight other electronic databases (including five clinical trials databases) and proceedings from pertinent scientific meetings. We attempted to contact the authors of trials reporting incomplete data but received no responses. We reviewed the bibliographies …

View Full Text